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ABSTRACT: Bacteria possess a remarkable ability to rapidly
adapt and evolve in response to antibiotics. Acquired antibiotic
resistance can arise by multiple mechanisms but commonly
involves altering the target site of the drug, enzymatically
inactivating the drug, or preventing the drug from accessing its
target. These mechanisms involve new genetic changes in the
pathogen leading to heritable resistance. This recognition
underscores the importance of understanding how such genetic
changes can arise. Here, we review recent advances in our
understanding of the processes that contribute to the evolution
of antibiotic resistance, with a particular focus on hypermutation mediated by the SOS pathway and horizontal gene transfer. We
explore the molecular mechanisms involved in acquired resistance and discuss their viability as potential targets. We propose that
additional studies into these adaptive mechanisms not only can provide insights into evolution but also can offer a strategy for
potentiating our current antibiotic arsenal.
“We are continually faced with a series of great opportunities
brilliantly disguised as insoluble problems.” - John W.
Gardner
The use of penicillin and sulfonamides in the 1940s markedthe start of a new era in the management of human health
and disease.1 The success of these drugs led to the enthusiastic
discovery of several new classes of antibiotics peaking during
the 1950s−1970s, a time now often termed the “golden era” of
antibiotic discovery. Unfortunately, for each new antibiotic class
discovered, reports of resistant microbes emerged within only a
few years, heralding the impending challenge of antibiotic
resistance.2,3
The rising tide of multi-drug-resistant organisms (MDROs)
is increasingly diminishing the efficacy of our antibiotic arsenal.4
This trend is in part due to the selection of resistant bacteria via
widespread use of antibiotics and the dissemination of
resistance genes in bacterial populations across the globe.5−7
Additionally, the unique pharmacological challenges of
targeting bacteria, coupled with economic disincentives to
developing antibiotics, have conspired to slow the rate of
discovery.8,9 Despite infection control efforts, resistance
continues to outpace drug discovery, raising the specter of a
“post-antibiotic era”, a time in the future when high mortality
caused by MDROs cannot be easily prevented.10
While innovative new approaches are underway to discover
antimicrobials with different mechanisms of action,11−13 the
most conventional approach to overcoming resistance has
involved the chemical modification of existing antibiotic
scaffolds.14 Our antibiotic arsenal has undergone a stepwise
tailoring of core structures, akin to evolution, to both increase
their spectrum of activity and overcome resistance mechanisms.
For example, antibiotics that maintain the β-lactam core started
with penicillins, moved forward through “generations” of
cephalosporins, and onward to carbapenems. While these
“next-generation” antibiotics could overcome some existing
resistance mechanisms, many bacteria, in turn, have rapidly
adapted to counteract these drugs (Figure 1).
These cycles of antibiotic discovery and resistance illustrate
the importance of understanding how drug resistance evolves,
which is the focus of this review. Although seemingly an
intractable problem, the evolution of antibiotic resistance may
represent a great opportunity. Indeed, efforts to understand the
evolution of drug resistance could serve a dual purpose:
providing a window into how bacteria adapt to harsh
environments while simultaneously elucidating novel targets
to potentiate our current antibiotic arsenal. Prior reviews have
introduced the concept of targeting evolution,15 and develop-
ments since have provided new insights into the mechanisms by
which genetic changes lead to heritable acquired resistance. In
this review, we focus on the biochemistry that mediates
genomic mutation by the bacterial SOS pathway or via
horizontal gene transfer (HGT). We conclude with a discussion
of the feasibility, challenges, and opportunities of targeting
these pathways.
■ ACQUIRED ANTIBIOTIC RESISTANCE
Antibiotic resistance can be classified as either intrinsic or
acquired, and by whether the mechanism involves a genetic
change. Intrinsic resistance refers to a generalizable trait that
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does not change regardless of antibiotic selective pressure. For
example, resistance to vancomycin for Gram-negative bacteria is
due to differences in their cell wall architecture relative to
Gram-positive bacteria and not a specific resistance mechanism.
By contrast, acquired resistance develops when a new trait is
expressed, often because of a genetic change that has been
selected for in the setting of antibiotic exposure. Bacteria can
also mediate tolerance to antibiotics independent of genetic
change, such as with persister states or biofilm formation.16
Genetic changes can confer resistance to antibiotics through
a diverse set of mechanisms. Though other mechanisms are
known, common and prominent examples include altering the
target site of the drug, enzymatically inactivating the drug, and
preventing the drug from accessing the target. Many of these
resistance mechanisms result either from a small number of
specific genomic mutations or, alternatively, from HGT (Figure
2). Point mutations can alter the interactions between a drug
and its target, as evidenced by mutations in RNA polymerase
that mediate resistance to rifampin. Point mutations can also
affect nontarget genes, as illustrated by promoter mutations
resulting in the overexpression of drug efflux pumps. Unlike
point mutations, HGT can result in the acquisition of genes
with entirely novel functions for the cell. For example, some
acquired genes can inactivate drugs, such as plasmid-encoded β-
lactamases. Others can even alter cellular metabolic or
structural products, as in the case with vancomycin-resistant
enterococci, where a cassette of genes mediates changes to a
peptidoglycan motif that dramatically weakens vancomycin
binding.17 While the genetic elements that directly confer
resistance have been well reviewed,18,19 the biochemical
mechanisms by which these genetic changes arise within
bacteria have been less scrutinized.
■ FIXED AND TRANSIENT HYPERMUTATION
Mutation is a major contributor to the evolution of drug
resistance. Some important pathogens, such as Mycobacterium
tuberculosis (Mtb), rely almost exclusively on mutagenesis,
rather than gene transfer, to evolve resistance.20 Similarly, for
certain classes of antibiotics, such as fluoroquinolones, point
mutations are the primary mechanism of acquired resistance.21
Furthermore, although mobile resistance genes largely account
for the high prevalence of MDROs, the evolution of these
genes against “next-generation” antibiotics also occurs at the
level of mutation.
Bacteria can acquire mutations spontaneously and at a
relatively constant rate because of the inherent mutational
frequency associated with genomic replication. However, under
various conditions, mutation rates can increase, in some cases
as high as 100-fold above the basal rates.22−24 Two basic
mechanisms are known to accelerate mutation in bacterial
strains: a loss of DNA repair or proofreading systems and the
induction of pro-mutagenic pathways.
The best-studied disruption in DNA repair involves loss of
mismatch repair (MMR). MMR deficiency can result in a f ixed
hypermutator phenotype where the organism’s mutation rate is
rendered constitutively high.24 The clinical implications of this
phenotype are evident in cystic fibrosis patients, where
hypermutator Pseudomonas aeruginosa strains with MMR
deficiency are frequently isolated.25 Interestingly, although
MMR deficiency is typically the result of a fixed loss of
function, bacterial strains that exhibit transient inactivation via
excision and reintegration of a cryptic prophage at a gene locus
critical for MMR function have also been isolated.26
While fixed hypermutators are important to acquired
resistance, the induction of transient pro-mutagenic pathways
is another important driving force for acquired antibiotic
resistance. Transient hypermutation has been linked to
conserved stress responses within bacteria.27,28 These stress
responses are mediated by tightly regulated genetic pathways
that poise bacteria to respond to a wide range of stressful
Figure 1. Cycles of drug discovery and antimicrobial resistance. An illustrative schematic is shown presenting several generations of β-lactam
antibiotics chronologically coupled to the β-lactamases that have emerged in clinical pathogens to counteract these “next-generation” antibiotics.
Figure 2. Acquisition and spread of antimicrobial resistance. Stress,
including treatment with antibiotics, promotes acquired resistance in
an initially sensitive strain by driving (A) mutagenesis or (B)
horizontal gene transfer. Strains with preexisting resistance can (C)
then spread by transmission between people.
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environments, from host immune systems to ultraviolet
radiation to toxic biomolecules, including antibiotics.29 Differ-
ent stress responses have been shown to contribute to
accelerated mutagenesis, including the starvation response
and envelope stress response;27,28 however, the majority of
studies on induced mutagenesis have focused on the bacterial
SOS pathway, where the biochemistry of the key players in the
pathway has been well-delineated.30,31 To this end, we next
turn our attention to the biochemistry of the SOS response and
opportunities for slowing acquired drug resistance by targeting
the sensor, regulator, or effector enzymes in the pathway.
■ TARGETING THE SOS RESPONSE
The SOS pathway is a widely conserved DNA damage response
pathway that, upon detection of DNA damage, responds by
expressing genes involved in DNA repair and damage tolerance
(Figure 3).30,31 SOS genes lie under the control of the
transcriptional repressor LexA. In the basal, unstressed state,
LexA binds to specific operator DNA (SOS box) sequences in
SOS gene promoters.32 In the setting of DNA damage, single-
stranded DNA (ssDNA) accumulates at stalled replication forks
and serves to activate the DNA damage sensor of the system,
RecA. Activated RecA stimulates LexA to undergo a self-
cleavage reaction, which promotes LexA dissociation and
derepression of SOS genes. The induced genes follow an
interesting chronology that implies a transition from high- to
low-fidelity repair, based on damage severity. Initially, repair
genes, including those for nucleotide excision repair, are
expressed; however, later in the SOS response, error-prone
translesion DNA polymerases are induced.33 Notably, LexA is
self-regulated, and re-accumulation of full-length LexA upon
rescue from damage can halt the SOS response. As a result,
DNA damage can cause a transient hypermutator phenotype,
known as SOS mutagenesis, which occurs for the duration of
the genotoxic stress.
Genetic experiments have validated the SOS pathway as an
important target for combating the evolution of antibiotic
resistance. Experimentally inactivating the SOS regulators,
either by deletion of recA or by engineering a noncleavable
LexA into the bacteria, renders the bacteria unable to initiate
the SOS response. These mutant bacteria are hypersensitive to
genotoxic antimicrobials and exhibit decreased mutation
rates.34−36 In a particularly revealing experiment, the
Romesberg group infected mice with either wild-type
Escherichia coli or E. coli harboring a noncleavable mutant of
LexA. Upon treatment with either rifampin or ciprofloxacin, the
wild-type infection showed an initial response to therapy but
then rebounded with drug-resistant bacteria. By contrast,
infection with the strain containing noncleavable LexA
continued on a trajectory toward eradication with no evidence
of detectable resistance.34 In a different experiment by the
Collins group, infecting drug-resistant E. coli with a phage
overexpressing a noncleavable LexA exerted a dominant-
negative effect that prevented SOS activation and resensitized
the E. coli to antibiotics.37 Preventing SOS activation has also
been reported to antagonize other mechanisms that mediate
survival in response to antibiotic stress, including integron-
mediated gene transfer, biofilm formation, and bacterial
persistence.34,38,39
With regard to SOS effectors, deletion of the SOS-induced
translesion polymerases decreases bacterial fitness, lowers their
mutation rate, and slows acquisition of drug resistance.40,41
Some of the most compelling evidence comes from studies in
Mtb. While the Mtb SOS operon contains fewer genes than
other pathogens, the key effector in the pathway is DnaE2, a
translesion DNA polymerase.42 Deletion of dnaE2 is associated
with decreased Mtb virulence in infection models and
suppresses the emergence of resistance to rifampin, a key
first-line anti-tuberculosis agent.40 Together, these genetic
studies suggest the potential therapeutic benefits of perturbing
the regulators or effectors of the SOS pathway.
The Damage Sensor, RecA. RecA is a highly conserved
∼38 kDa protein that plays a critical role in homologous
recombination and also acts to stimulate LexA self-cleavage.43
Structurally, monomeric RecA consists of three domains with a
central core RecA fold that is flanked by smaller regulatory
domains.44 These monomers can form large nucleoprotein
filaments on ssDNA (Figure 4A), which can extend across
thousands of base pairs via cooperative oligomerization
mediated by the core RecA fold.45 Filamentous RecA has a
deep helical groove that envelopes, stretches, and unwinds the
bound DNA, preparing it for homology searching and
subsequent DNA strand exchange. The core RecA fold binds
ATP at the monomer−monomer interface (Figure 4A).44
While only binding of ATP is required for filament formation
and simple DNA strand exchange reactions, RecA also catalyzes
ATP hydrolysis, which is important for filament depolymeriza-
tion as well as some specific types of recombination activities.43
Filamentous RecA acts as a co-protease to stimulate self-
cleavage of LexA (discussed below), as well as other related
members of the LexA/signal peptidase superfamily, such as
phage λ repressor and UmuD in E. coli. In the case of phage
repressor, cleavage stimulates the prophage to enter the lytic
cycle.46 Interestingly, RecA serves two roles in association with
UmuD: it stimulates self-cleavage of UmuD to UmuD′ and is
also, itself, an essential component of the associated Pol V
mutasome.47 The LexA binding site on the RecA filament has
not been fully elucidated, but current models suggest that LexA
may span adjacent RecA monomers across the deep helical
groove.48 ATP binding, but not hydrolysis, is required for the
co-protease activity.
As ΔrecA strains are hypersensitive to antibiotics and less
prone to acquired resistance,35,36 RecA has been proposed as a
novel target for slowing the evolution of antibiotic resistance.
The feasibility of targeting RecA is further supported by the
existence of biological protein modulators of RecA, including
RecX and DinI, which both can antagonize SOS induction.49 In
an effort to discover small molecule RecA inhibitors, Singleton
Figure 3. The SOS response is a key regulator of transient
hypermutation in bacteria. Activation of the stress sensor, RecA (red
ovals), promotes self-cleavage of the SOS regulator, LexA (blue ovals).
LexA cleavage results in induction of the SOS effectors, which include
error-prone DNA polymerases (green circles) that can bypass DNA
lesions leading to mutations during error-prone repair.
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and colleagues have designed several high-throughput screens
largely focused on E. coli RecA ATPase activity and identified
potential inhibitors.50−53 While antimicrobial activity against E.
coli has not yet been described, one lead RecA probe, suramin,
was characterized against Mtb, where the inhibitor was
suggested to potentiate the activity of the fluoroquinolone
ciprofloxacin.54 Although studies aimed at inhibiting RecA are
promising, specificity is one important consideration that needs
to be explored. In mammals, RecA has up to seven important
homologues (Rad51 family).55 In this context, rational
approaches using nucleotide analogues to target RecA’s ATP
binding site have been examined to a limited extent.56 These
offer a potential starting point for applying strategies that have
yielded analogous protein kinase inhibitors that are ATP
competitive and selective.57
The Regulator, LexA. The ∼22 kDa LexA molecule
consists of two domains separated by a short flexible linker and
exists as a homodimer in solution. The N-terminal domain
(NTD) contains specific DNA binding activity, and the C-
terminal domain (CTD) contains protease activity (Figure
4B).58,59 Dimeric LexA binds to SOS box DNA through a
winged helix−turn−helix motif in the NTD with dimerization
mediated by the CTDs.59 The CTD contains a protease active
site, with a serine-lysine catalytic dyad. Self-cleavage occurs at a
protein loop in the same monomer, located near the linker
between the two domains.58 Crystal structures of well-
characterized LexA mutants show that this cleavage loop can
exist in two distinct states. In the “non-cleavable” state, the loop
is far removed from the active site. In the “cleavable” state, it
undergoes a large ∼20 Å conformational change, positioning
the scissile peptide bond adjacent to the active site serine.58
Interestingly, in the “cleavable” state, LexA binds its peptide
substrate in a sharp β-turn, rather than the extended β-sheet
peptide conformation common to canonical proteases.58,60
Given the promising genetic studies on bacteria with
noncleavable LexA discussed above, small molecule inhibition
of LexA’s protease domain has been proposed.15,34 To this end,
while LexA’s distinct active site architecture offers potential
advantages, it also poses two major challenges. First, as the
substrate is tethered in cis, any competitive inhibitor will have
to overcome the high local substrate concentration of the
internal cleavage loop. Indeed, LexA shows inhibition only
under large excesses of nonspecific protease inhibitors, such as
diisopropyl fluorophosphates.61 Second, given self-cleavage,
classical high-throughput protease assays, such as using
fluorophore quencher-containing peptides in trans, cannot be
readily translated to LexA. Despite these challenges, rational or
screening-based approaches to the discovery of LexA inhibitors
are well-justified.
To help inform rational inhibitor discovery efforts, we have
performed extensive mutagenesis of LexA to elucidate the
substrate specificity determinants.62 These experiments sug-
gested that several residues within the cleavage loop make
essential recognition contacts, while other specificity determi-
nants are likely involved in facilitating LexA’s conformational
change. Interestingly, stabilization of the β-turn within the
cleavage loop accelerates self-cleavage, suggesting that small
cyclic peptides may be tractable rational inhibitor starting
points.62 Alternatively, allosteric inhibitors that prevent LexA’s
conformational change or small molecules that could disrupt
the LexA−RecA interface are viable strategies for LexA
inhibition; however, our understanding of the biochemical
mechanisms involved is incomplete. Despite the available
structural snapshots, the basis for LexA’s conformational
dynamics has not been elucidated and, in particular, the
LexA−RecA interface remains poorly characterized despite
dedicated efforts.63,64 Further studies are required to under-
stand these essential elements of RecA-induced LexA catalysis
to help drive the discovery of potential SOS inhibitors.
Figure 4. Targets of the SOS pathway. (A) Structure of the SOS sensor, RecA, shown as a filament (PDB entry 3CMV), with alternating monomers
colored dark or light blue. The ssDNA is shown as red spheres. The panel below is a close-up of the ATP binding pocket (PDB entry 1XMS), a site
that could be targeted. (B) Shown is dimeric LexA, bound to SOS box DNA (PDB entry 3JSO), with individual monomers colored green and
yellow. The C-terminal protease domain (CTD) is connected to the N-terminal DNA binding domain (NTD) by a structurally unresolved linker
(dashed line). In the self-cleavage mechanism, LexA undergoes a large conformational change in its C-terminal domain between inactive (red sticks,
PDB entry 1JHC) and active states (purple sticks, PDB entry 1JHE) that positions the cleavage loop within the active site, adjacent to the Ser/Lys
dyad. The overlaid active and inactive conformations are shown in the bottom panel. (C) Shown is a representative Y-family polymerase, Dpo4, an
error-prone polymerase, bound to DNA (PDB entry 1JX4). Unlike high-fidelity T7 polymerase, shown for comparison (PDB entry 1T7P), Dpo4
possesses a more open, exposed catalytic site, which reduces the selectivity for the incoming nucleotide, colored green.
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The Effector, Error-Prone Polymerases. Foremost
among the effectors in SOS mutagenesis are DNA polymerases
(Pol II, IV, and V in E. coli).33 These polymerases catalyze
translesion synthesis (TLS) by replacing the replicative Pol III,
which stalls when encountering a damaged DNA template.65
The ability of these polymerases to catalyze TLS, however, is
associated with an increased frequency of mutation because of
the lack of 3′−5′ exonuclease proofreading activity, weak
processivity, and low fidelity.66,67
Several of the critical enzymes involved in TLS, including Pol
IV and Pol V in E. coli, are dissimilar enough from replicative
polymerases that their identity as DNA polymerases came long
only after the discovery of their role in mutagenesis.24,68 Crystal
structures of several of these “Y-family” DNA polymerases have
yielded insight into their function and fidelity (Figure 4C).
Despite a low level of sequence identity, the error-prone
polymerases share the palm, finger, and thumb domains
characteristic of their high-fidelity relatives (Figure 4C);69−71
however, a detailed comparison shows structural differences
that likely account for their lower fidelity.24,72,73 The finger and
thumb domains of the error-prone polymerases are in general
shorter and appended with an additional domain known as the
little finger domain, which has specialized function in Y-family
polymerases. Further, O-helices, which typically play a role in
proper Watson−Crick base pairing, are absent from the finger
domains. Overall, these modifications result in a more flexible
and open active site that may facilitate TLS over DNA damage
due to bulky adducts or strand cross-links. Notably, elegant
studies using FRET or time-resolved crystallography have
demonstrated that, despite the appearance of a more static
open active site, enzyme dynamics are critical to lesion bypass
and catalysis.74,75
The importance of these error-prone polymerases in
generating mutation and resistance, combined with their
relaxed fidelity, suggests the opportunity to inhibit these
enzymes with small molecules. While to the best of our
knowledge no specific inhibitors of bacterial Y-family
polymerases have been discovered, there is a rich precedent
for use of specific nucleotide drugs to combat viral infection or
cancer. The structural features of Y-family polymerases could
potentially be exploited to achieve the required specificity
needed for a polymerase inhibitor. For example, the more open
active site and lack of requirement for canonical Watson−Crick
base pairing may permit incorporation of bulky chain-
terminating nucleotides that would be discriminated against
by high-fidelity polymerases. Because genotoxic antibiotics
induce the expression of these error-prone polymerases, Y-
family polymerase inhibitors would be predicted to synergize
with SOS-inducing antibiotics.
■ TARGETING GENE TRANSFER
While hypermutation results in the production of novel
antibiotic resistance determinants by small, relatively random
mutations, which are not subjected to selection until after their
inception, HGT involves DNA that has already survived
selective forces. Gene transfer is therefore a highly efficient
mechanism for bacteria to evolve and adapt, and the process
has resulted in the massive dissemination of antibiotic
resistance genes among, and between, different bacterial
species. HGT has been shown to occur in highly diverse
environments, ranging from the soil to intensive care units in
hospitals to the human microbiome.76−78 The clinical
importance of HGT is highlighted by examples such as the
emergence and recent dissemination of carbapenem-resistant
Enterobacteriaceae.79 For example, several reports on individual
patients harboring Klebsiella pneumoniae with plasmid-encoded
resistance to carbapenems have shown that other species, such
as E. coli or Serratia marcescens, could be isolated from the same
patient containing the identical resistance plasmid, suggesting
the occurrence of HGT within the patient’s microbiome.79,80
Notably, the exchange of genetic information appears to be
dependent on time. As a recent example, genomic studies of the
gut microbiota of more than 100 healthy individuals revealed
the presence of numerous antibiotic resistance genes in the
human gut and showed that the diversity of these resistance
genes increased with an individual’s age.81
Despite the prominent role of HGT in the spread of
antibiotic resistance, critical aspects of these processes remain
poorly understood and present challenges to the idea of
therapeutically targeting HGT. For instance, although the
frequency of bacteria harboring antibiotic resistance determi-
nants on mobile DNA (i.e., the end products of HGT) within
certain environments is becoming better appreciated, the
timing and location of HGT within and between different
clinically relevant ecosystems remain to be elucidated. Without
this information, it is difficult to predict the impact of active
HGT in clinical models, especially when considering specific
environments (e.g., intensive care units vs the microbiome of an
individual patient). Furthermore, unlike the conserved SOS
response, HGT mechanisms are highly diverse, making the
targeting of HGT conceptually more difficult. Despite these
clear challenges, the dire need for novel therapeutic paradigms
highlights the importance of seeking out commonalities in
HGT mechanisms and exploring the plausibility of targeting
these pathways.
The movement of large DNA blocks can be broken into two
general steps: DNA recombination and transport (Figure 5).
Both recombination and transport are subject to regulation by
stress responses. As an example, lytic gene expression of many
temperate phages has long been known to be triggered by
bacterial stress, in particular the SOS response (described
above). More recent insights into the regulation of gene
transfer, however, suggest this may be a broad theme. For
instance, functional SOS boxes have been found within
integrons and shown to regulate activation of the gene transfer
by controlling expression of the integrase gene.38 Likewise, in
pathogens such as Vibrio cholerae, a large integrative and
conjugative element encoding resistance to multiple antibiotics
is under the control of a LexA homologue, SetR, which also
requires SOS activation for mobilization.82 Additionally, stress-
linked mobile elements are also critical to causing disease,
including the superantigens encoded by pathogenicity island
genes in Staphylococcus aureus or Shiga-toxin production by
some enteric pathogens.83,84 Stress responses have further been
linked to natural competency in Streptococcus pneumoniae and
can enhance conjugational recombination rates.85,86 Thus, like
SOS mutagenesis, gene transfer events that lead to acquired
antibiotic resistance are closely linked to stress.
Specialized DNA Recombination and Mobile DNA.
HGT is mediated by natural competency and transformation,
transduction, and conjugation, with the latter mechanisms
being more common in clinical isolates.87 Whereas plasmid
DNA can be maintained outside the chromosome, the life cycle
of other types of mobile DNA relies on recombination with the
host chromosome (Figure 5). These mobile DNA elements
vary greatly in size and complexity, but all encode a specialized
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recombination enzyme. These enzymes catalyze DNA break-
ing−joining reactions at the element termini, thus allowing for
mobilization of the DNA element from its chromosomal site to
distant sites. The simplest mobile element, the insertion
sequence (IS), encompasses only a transposase enzyme and a
pair of short inverted repeat sequences that flank the
transposase gene and function as recognition sites where the
DNA breaking−joining reactions occur. Transposons are more
complex, with a set of inverted repeats that capture additional
genes between them. Finally, bacteriophage elements may be
more complex yet, encoding all the proteins necessary to
conduct the infectious life cycle. Thus, unlike a simple IS, a
transposon or phage is capable of mobilizing accessory genes
that aid in its own dissemination, often by accumulating and
evolving genes that endow its host with an increased rate of
survival or pathogenicity such as virulence factors and antibiotic
resistance determinants.88
Integrons make up a related class of DNA elements that
function as gene assembly platforms to direct the expression of
exogenous genes.89 As with transposons, integrons may
similarly be enriched with antibiotic resistance and virulence
genes. Whereas transposons “hop” from location to location,
occasionally capturing functionality along the way, integrons are
stationary elements that collect exogenous genes and insert
them into their DNA locus. Remarkably, once a set of genes is a
part of the integron, the integrase enzyme can catalyze the
rearrangement of those genes with respect to the promoter,
thus changing which genes are expressed. In this way, integrons
can serve as a cache of antibiotic-resistant genes to be deployed
for future use if needed.
The two major classes of specialized recombination enzymes
are site-specific recombinases and transposases. Both conduct
transesterification reactions of the DNA phosphodiester
backbone without a requirement for high-energy cofactors
such as ATP.90,91 Site-specific recombinases contain an active
site Tyr (or Ser) residue, which forms a covalent intermediate
with the DNA backbone. This allows them to conduct a
conservative two-step reaction that catalyzes strand exchange
between two different pieces of double-stranded DNA
(dsDNA), resulting in an intact, ligated dsDNA product.
Bacterial transposases generally fall into the DDE/integrase
superfamily of enzymes, containing protein folds remarkably
similar to integrases encoded by retroviruses.92 The protein
folds of these enzymes are topologically similar and bring at
least three acidic residues (typically DDE) in the proximity of
one another.92 The active site acidic residues bind divalent
metal cations, required cofactors for catalysis, which promote
transesterification reactions via a two-metal ion mechanism
without any protein−DNA covalent intermediate.93,94
Although there have been only a few studies identifying small
molecule inhibitors of specialized bacterial recombination
enzymes, the targeting of the retroviral integrase of HIV-1, a
prominent integrase/DDE superfamily member, has been a
significant clinical achievement and serves as a model for efforts
to inhibit other specialized recombinases. The crystal structure
of the Prototype Foamy Virus (PFV) retroviral integrase bound
to donor DNA and different strand transfer inhibitors has been
determined (Figure 5).93 The structure supports a model in
which the “diketo acid-like” pharmacophore of the inhibitors
binds to the two active site divalent cations of the activated
enzyme−donor DNA intasome complex. Inhibitor binding
displaces the reactive 3′-OH of the donor DNA, thus
deactivating the complex and inhibiting strand transfer. Diketo
acid-like inhibitors have also been found for the Holliday
junction (HJ) resolving enzyme encoded by poxviruses and for
the Tn5 transposase,95,96 suggesting that the motif may
represent a general scheme for inhibiting members of this
enzyme family. Small peptide inhibitors of site-specific Tyr
recombinases that specifically bind to HJ DNA to interrupt
enzymatic DNA transactions have also been identified.97 One
candidate peptide was able to block prophage excision by
trapping such an intermediate, which also additionally resulted
in antimicrobial activity, perhaps because of interference with
DNA replication and repair.98
DNA Transport. For a DNA molecule to transfer between
bacteria, it must cross lipid membranes, which is energetically
disfavored. Large multiprotein molecular machines for natural
competency, conjugation, and transduction allow for DNA
shuttling and therefore represent potential targets for
preventing the spread of resistance determinants (Figure 5).
We refer our readers to recent reviews covering the molecular
mechanisms and structural biology of each of these topics,
noting that targeting of these processes with small molecules is
virtually unexplored.99−101 However, here we will highlight
recent discoveries regarding the inhibition of a bacterial
conjugation system with small molecules developed through
rational design.
In bacterial conjugation, one strand (T-strand) of a dsDNA
plasmid is transferred between organisms, ultimately resulting
in the complete transfer of the genetic information encoded on
the plasmid. The major components of conjugation are a
relaxase enzyme, a type IV coupling protein (T4CP), and the
membrane pore and pilus of a type IV secretion system (T4SS).
Figure 5. DNA recombination and transport are targets of horizontal
gene transfer. Within the donor cell, site-specific recombination and
transposition reactions (black arrows) can mobilize antibiotic
resistance genes (blue rectangles) to the DNA transport machinery
of a bacteriophage (transduction) or a type IV secretion system
(conjugation). Environmental naked DNA can be taken up by natural
competency (transformation). Once inside the recipient cell, the
antibiotic resistance gene may be maintained within a plasmid or
recombine with the recipient genome. DNA recombination could be
targeted by inhibiting the DDE/integrase family of transposases: a
related retroviral integrase is shown in complex with the small
molecule raltegravir (PDB entry 3OYA). DNA transport could be
targeted by inhibiting relaxase enzymes: the nicking enzyme of S.
aureus is shown in complex with oriT DNA (PDB entry 4HT4).
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The relaxase enzyme, often as part of a multiprotein
“relaxasome”, recognizes the origin of transfer (oriT) sequence
on the plasmid and nicks the T-strand to form a covalent 5′-
phosphotyrosine linkage, thus creating a free DNA end to be
transported through the membrane pore of the T4SS. After
DNA transport and synthesis of the complementary strand,
relaxase again nicks oriT, this time resulting in release and
recircularization of the T-strand.
Recently, the Redinbo laboratory has discovered inhibitors
for two types of relaxase enzymes using rational design based
on structural insights. First, they determined the structure of an
F-plasmid relaxase, whose catalytic cycle includes two
simultaneous phosphotyrosine linkages to oriT. In the structure,
they observed that a single divalent metal ion stabilized the
formation of both phosphotyrosine linkages. On this basis, they
reasoned that bisphosphonates could serve as functional mimics
and potential inhibitors. After a directed screen against a small
library of bisphosphonates, they found several that inhibited
relaxase in vitro and inhibited conjugation in a relaxase and F-
plasmid-dependent manner in cell-based assays.102 In a
different study, the group also determined the crystal structure
of the nicking enzyme of S. aureus (NES) in complex with oriT
DNA (Figure 5). NES is present on clinically important
conjugative plasmids known to result in vancomycin-resistant S.
aureus. Unlike the F-plasmid relaxase, NES forms only one
phosphotyrosine linkage. In this case, catalysis could be
disrupted using a small polyamide designed to bind specifically
to a five-nucleotide region of oriT that makes critical contacts
with NES.103
These examples, although preliminary, suggest specific
targeting of the relaxasome is feasible and highlights the
potential clinical utility of inhibitors of bacterial conjugation.
Interestingly, in the F-plasmid case, inhibition of the relaxasome
led to cell death.102 Because gene transfer mechanisms are
highly activated during antibiotic stress, this finding raises the
interesting possibility that inhibiting effector pathways in
creative ways could not only curtail gene transfer but also
lead to cell death by poisoning the cell with trapped
intermediates.
■ OPPORTUNITIES AND CHALLENGES FOR
TARGETING THE EVOLUTION OF RESISTANCE
We have provided an overview of two mechanisms for the
evolution and spread of antibiotic resistance within and
between organisms: stress-induced mutagenesis caused by the
SOS pathway and acquisition of resistance genes by HGT.
Studying these and related pathways could not only provide
insight into how bacteria evolve and adapt but also expose
weaknesses that we are hopeful can be exploited in the form of
new, “anti-evolutionary” therapeutics.
Pursuit of such therapies will pose a unique set of challenges
and open up new areas of inquiry. As one notable challenge,
purely anti-evolutionary drugs will not reverse preexisting
genetic resistance in either nature or patients. Indeed, this
problem is ancient and embedded in natural history, as the
analyses of bacteria present before the rise of civilization have
shown that antibiotic resistance genes far predate our use of
antibiotics.104 However, rather than focusing on the existing
pool of resistance, we posit that anti-evolutionary agents could
prevent, or at least delay, the de novo generation and acquisition
of resistance in pathogens. Clinical cases in which pathogens
are repeatedly exposed to antimicrobial therapy, as in the case
of cystic fibrosis, severely immunosuppressed patients,
complicated medical device infections, or mycobacterial
infections, are the main areas in which such novel therapies
might be employed. Additionally, the examples of the SOS
response, prophage excision, and relaxase function suggest
targeting of these processes can potentially lead to the
accumulation of toxic intermediates and cell death.37,98,102
Further, as stress responses are linked to bacterial persistence,
biofilm formation, and the expression of virulence factors,
targeting evolutionary processes may decrease pathogenic-
ity.11,105,106 In the case of HGT-mediated antibiotic resistance,
while there is an assumption that all clinically relevant gene
transfer events have already occurred by the time a patient
shows signs of an infection, we do not know the timing of such
events and, at a minimum, preventative strategies for patients at
high risk of acquiring new resistant pathogens via HGT could
be entertained. Despite challenges, the impetus for pursuing
anti-evolutionary drugs comes from their potential to offer a
one−two punch, potentiating the action of existing antibiotics
that trigger stress responses and blocking the development of
resistance.
Our overview also highlights the gaps in basic science
knowledge regarding how to assess the clinical viability of
targeting evolution. With genomic advances, we are learning
more about the relative frequencies of clinically relevant
resistance determinants. Many studies are also beginning to
look at transmission events between patients within hospital
settings, and even the molecular relationship between resistance
genes found in human pathogens and the environment.107−109
However, insight into the relative rates, timing, and location of
each of these events remains lacking. Does antibiotic stress
enhance the mutation rate to a degree that has biological
consequences within an individual patient? What is the rate of
clinically relevant HGT within microbial ecosystems such as the
human gut? A similar set of questions applies to understanding
the clinical relevance of nongenetic mechanisms for antibiotic
tolerance, such as bacterial persistence and biofilm formation.
This type of knowledge, broken down by relevant ecosystem
and pathogen, and coupled to the kinetics of the biochemical
steps, would offer enormous insight into which mechanisms to
target, as it would tell us what the “rate-limiting” steps are in
evolution and adaptation to antibiotics. We are hopeful further
technological advances in DNA sequencing and microbiome
research will lead to answers to these questions.
On the surface, the problem of antibiotic resistance appears
insurmountable, but bridging the gaps in our knowledge holds
the promise of unmasking great opportunities to intervene. The
scale of the clinical problem suggests the need for innovative
new approaches to antibacterials. It is our hope that these
efforts will take many forms: from augmenting natural product
discovery by accessing the uncharted molecular diversity
present within “unculturable” organisms to counteracting
nongenetic mechanisms that mediate antibiotic tolerance and,
finally, targeting the very mechanisms that underpin the
evolution of genetic resistance.12,13,105
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